Identification of RALA as a Therapeutic Target and Prognostic Predictor of Osteosarcoma

Figure 5

Clinical analyses based on RALA. (a, b) Overall survival (a) and disease-free survival (b) of 100 patients undergoing surgical procedures between 2007 and 2022 were analyzed using Kaplan-Meier analysis. (c–f) Subgroup analyses were performed using Kaplan-Meier analysis. (g, i) Univariate/multivariate Cox proportional hazards regression analyses results of disease-free survival were aggregated using forest plots (g) and risk score plots (i). (h, j) Univariate/multivariate Cox proportional hazards regression analyses results of overall survival were aggregated using forest plots (h) and risk score plots (j). (k–m) Sensitivity and accuracy of nomogram graphs (k) based on RALA were verified by time-dependent ROC curve (l) and calibration model (m). (n–p) 1 (n), 3 (o), and 5 (p) years’ benefits from RALA measures in predicting survival outcomes were calculated using DCA curves.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)

(m)

(n)

(o)

(p)